APA (7th ed.) Citation

Solomon, B., Drilon, A., Lin, J., Bazhenova, L., Goto, K., De Langen, J., . . . Besse, B. (2023). 1372P Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: Update from the phase I/II TRIDENT-1 trial. Annals of Oncology, 34, S787. https://doi.org/10.1016/j.annonc.2023.09.2405

Chicago Style (17th ed.) Citation

Solomon, B.J, et al. "1372P Repotrectinib in Patients (pts) with NTRK Fusion-positive (NTRK+) Advanced Solid Tumors, Including NSCLC: Update from the Phase I/II TRIDENT-1 Trial." Annals of Oncology 34 (2023): S787. https://doi.org/10.1016/j.annonc.2023.09.2405.

MLA (9th ed.) Citation

Solomon, B.J, et al. "1372P Repotrectinib in Patients (pts) with NTRK Fusion-positive (NTRK+) Advanced Solid Tumors, Including NSCLC: Update from the Phase I/II TRIDENT-1 Trial." Annals of Oncology, vol. 34, 2023, p. S787, https://doi.org/10.1016/j.annonc.2023.09.2405.